Other Events ·
Moleculin Biotech, Inc. announced positive preliminary unblinded efficacy results from the first 45 patients in Part A…
MBRXMoleculin Biotech, Inc.
Moleculin Biotech, Inc. announced positive preliminary unblinded efficacy results from the first 45 patients in Part A of its pivotal Phase 2/3 MIRACLE trial. The Annamycin treatment arms showed favorable efficacy trends compared to the control arm in patients with relapsed or refractory acute myeloid leukemia (R/R AML). Moleculin Biotech, Inc. is a biotechnology company focused on developing therapeutic solutions for hematologic malignancies.